MedPath

UK's Clinical Trial Diversity Plan to Pilot with Sponsors in 2025

  • The UK's new Inclusion & Diversity Plan is set to pilot in 2025, inviting trial sponsors to submit diversity plans with trial applications.
  • The initiative follows a consultation period that garnered over 200 stakeholder responses, shaping the guidance for clinical trial diversity.
  • The plan includes questions for trial sponsors to consider, aiming to enhance diversity and inclusion in clinical research.
The UK's Inclusion & Diversity Plan is set to launch a pilot program in 2025, inviting clinical trial sponsors to submit diversity plans as part of their trial applications. This initiative follows the conclusion of a consultation period that received over 200 responses from various stakeholders.
The Inclusion & Diversity Plan outlines specific questions for trial sponsors to address, aiming to improve representation and inclusivity in clinical trials. The pilot program seeks to test the feasibility and effectiveness of these guidelines in real-world settings, gathering data to further refine the approach. The goal is to ensure that clinical research reflects the diversity of the UK population, leading to more equitable healthcare outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Finalized Diversity in Clinical Trials Guidance and Revised Short Form Consent Policy Implemented

The University of Washington has announced the finalization of the Diversity in Clinical Trials Guidance and the implementation of a Revised Short Form Consent Policy, effective from January 1, 2026. These changes aim to improve participation from underrepresented communities in clinical trials and streamline the consent process for non-English speaking participants.

FDA Updates Guidance to Enhance Diversity in Clinical Trials

The FDA has updated its guidance, mandating that clinical trial sponsors create diversity action plans (DAPs) to boost the enrollment of underrepresented groups.

UK Clinical Trial Regulations Undergo Major Overhaul to Streamline Approvals and Boost Transparency

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is implementing significant changes to clinical trial regulations, the most substantial in 20 years, to enhance the UK's appeal as a global research hub.

FDA's Draft Guidance on Clinical Trial Diversity: Challenges and Implications for Pharma

The FDA's draft guidance on diversity action plans (DAPs) aims to increase the enrollment of underrepresented populations in clinical trials, focusing on age, sex, race, and ethnicity.

FDA's Draft Guidance on Clinical Trial Diversity: Challenges and Implications

The FDA released draft guidance on diversity action plans (DAPs) to boost the enrollment of underrepresented groups in clinical trials, focusing on age, sex, race, and ethnicity.

MyMelanoma Study Joins NHS DigiTrials to Enhance Melanoma Research

The MyMelanoma study, the UK's largest melanoma research project, has been selected for the NHS DigiTrials initiative.

UK Dementia Trials Accelerator Aims to Radically Increase Clinical Trial Participation

The Dementia Trials Accelerator will receive £20m in government funding to significantly increase UK participation in dementia clinical trials.

FDA Diversity Guidance Drives EHR and AI Integration in Clinical Trials

The FDA's draft guidance on Diversity Action Plans requires clinical trial sponsors to demonstrate consideration towards trial representation, impacting Phase 3 studies.

FDA Issues New Guidance to Enhance Diversity and Efficiency in Clinical Trials

The FDA has finalized guidance on decentralized clinical trials (DCTs), enabling study activities at patients' homes and local healthcare facilities.

FDA Issues Draft Guidance on Diversity Action Plans for Clinical Studies

The FDA released draft guidance on Diversity Action Plans (DAPs) to boost enrollment of underrepresented groups in clinical trials, as mandated by FDORA 2022.

Reference News

[1]
UK's Clinical Trials Diversity Draft Gets Over 200 Stakeholder Responses
pink.pharmaintelligence.informa.com · Nov 29, 2024

UK's clinical trials diversity draft received over 200 stakeholder responses; a pilot for submitting diversity plans in ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy